SEARCH

SEARCH BY CITATION

References

  • 1
    First Australian Conference on Hepatitis C. Confernce Proceedings, Sydney 1997.
  • 2
    HIV and related diseases in Australia. Annual Surveillance Report, National Centre in HIV Epidemiology and Clinical Research 1998.
  • 3
    Farrel G. Chronic viral hepatitis. Med J Aust 1998;168:619626.
  • 4
    Alter MJ. Mast EE, Moyer LA, Margolis HS. Hepatitis C. Infect Dis Clin North Am 1998;12:1326.
  • 5
    Molinari JA. Hepatitis C virus infection. Dent Clin North Am 1996;40:309325.
  • 6
    Roffi L., Ricci A., Ogliari C., et al. HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. J Hepatol 1998; 29:701706.
  • 7
    Chem M., Sallberg M., Sonnerborg A., et al. Limited humoral immunity in hepatitis C virus infection. Gastrenterlogy 1999; 116:135143.
  • 8
    Thomson JA, Rodger AJ, Thompson SC, et al. The prevalence of hepatitis C in patients admitted with acute hepatitis to Fairfield Infectious Diseases Hospital 1971–1975. Med J Aust 1998; 169:360363.
  • 9
    Poynard T., Marcellin P., Lee SS, et al. Randomised trial of interferon α 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:14261432.
  • 10
    Guido M., Rugge M., Jara P., et al. Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology 1998; 115:15251529.
  • 11
    Bonkovsky HL, Woolley JM. Reduction of health-realted quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999;29:264270.
  • 12
    Farrell G. Interferon treatment for chronic viral hepatitis in Australia: is it worth it? Med J Aust 1992;156:873875.
  • 13
    Del Pozo MA, Arias JR, Pinilla J. et al. Interferon alpha treatment of chronic hepatitis C in HIV-infected patients receiving zidovudine: efficacy, tolerance and response related factors. Hepato-Gastrenterology 1998; 45:16951701.
  • 14
    Whyte GS, Savoia HF. The risk of transmitting HCV, HBV or HIV by blood transfusion in Victoria. Med J Aust 1997;166:584586.
  • 15
    Heintges T., Mohtr L., Niederau C., et al. Quantitaive hepatitis C RNA-polymerase chain reaction and detection with DNA-ELIS. Hepatogastrenterology 1998; 45:16841689.
  • 16
    Alter MJ, Moyer LA. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18 (Suppl 1):S610.
  • 17
    Flamm SI, Parker R., Chopra S. Risk factors associated with chronic hepatitis C virus infection: limited frequency of an unidentified source of transmission. Am J Gastroenterl 1998;93:597600.
    Direct Link:
  • 18
    Crofts N., Aitken CK, Kaldor JM. The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. Med J Aust 1999;170:220221.
  • 19
    Lin R., Dutta U., Kaba S., et al. Effects of hepatitis G virus coinfection o n severity of hepatits C: Relationship to risk factors and response to interferon treatment. J Gastroenterol Hepatol 1998; 13:773780.
  • 20
    Chem M., Yun ZB, Sallberg M., et al. Detection of hepatitis C virus RNA in the cell fraction of saliva before and after oral surgery. J Med Virol 1995; 45:223226.
  • 21
    Porter SR, Lodi G. Hepatitis C virus (HCV) - an occupational risk to dentists? Br Dent J 1996;180:473474.
  • 22
    Fagan EA, Partridge M., Sowaray JH, Williams R. Review of hepatitis non-A, non-B: the potential hazards in dental care. Oral Surg Oral Med Oral Pathol 1988;65:167171.
  • 23
    Epstein JB, Sherlock CH. Hepatitis C: rapid progress in medicine and implications for dentistry. J Can Dent Assoc 1994;60:323329.
  • 24
    Thomas DI, Gruninger SE, Siew C., et al. Occupational risk of hepatitis C infections among general dentists and oral surgeons in North America. Am J Med 1996; 100:4145.
  • 25
    Dryer AF, Aspinall S., Jacobs, FJ. Prevalence of Markers for human immunodeficiency, hepatitis B and hepatitis C viruses in maxilliofacial and oral surgery patients at Medunsa. J Dent Assoc S Afr 1993;48:377380.
  • 26
    Epstein JB, Porter SR, Scully C. Non-A, non-B hepatitis and dentistry: a status report for the American Journal of Dentistry. Am J Dent 1992;5:4945.
  • 27
    Piazza M., Borgia G., Picciotto L., et al. Detection of hepatitis C virus-RNA by polymerase chain reaction in dental surgeries. J Med Virol 1995; 45:4042.
  • 28
    Wisnom CJ, Kelly M. Medical/dental management of a chronic hepatitis c Patient. Oral Surg Oral Med Oral Pathol 1993;75:786790.
  • 29
    Weiss K. Hepatitis C: what a dentist should know. J Can Dent Assoc 1995; 61:537540.
  • 30
    Coates EA, Brennan D., Logan RM, et al. Hepatitis C infection and associated oral health problems. Aust Dent J 2000; 45:108114.
  • 31
    Carrozzo M., Gandolfo S., Lodi G., et al. Oral lichen planus in patients infected or noninfected with hepatitis C virus: the role of autoimmunity. J Oral Pathol Med 1999; 28:1619.
  • 32
    Gorsky M., Raviv M., Moskona D., et al. Clinical characteristics and treatment of patients with oral lichen planus in Israel. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 82:644649.